Literature DB >> 18073397

Pathogen-directed therapy in acute exacerbations of chronic obstructive pulmonary disease.

Fernando J Martinez1.   

Abstract

Acute exacerbations of chronic obstructive pulmonary disease (COPD) are important events in the natural history of this chronic lung disorder. These events can be caused by a large number of infectious and noninfectious agents and are associated with an increased local and systemic inflammatory response. Their frequency and severity have been linked to progressive deterioration in lung function and health status. Infectious pathogens ranging from viral to atypical and typical bacteria have been implicated in the majority of episodes. Most therapeutic regimens to date have emphasized broad, nonspecific approaches to bronchoconstriction and pulmonary inflammation. Increasingly, therapy that targets specific etiologic pathogens has been advocated. These include clinical and laboratory-based methods to identify bacterial infections. Further additional investigation has suggested specific pathogens within this broad class. As specific antiviral therapies become available, better diagnostic approaches to identify specific pathogens will be required. Furthermore, prophylactic therapy for at-risk individuals during high-risk times may become a standard therapeutic approach. As such, the future will likely include aggressive diagnostic algorithms based on the combination of clinical syndromes and rapid laboratory modalities to identify specific causative bacteria or viruses.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 18073397      PMCID: PMC2647652          DOI: 10.1513/pats.200707-097TH

Source DB:  PubMed          Journal:  Proc Am Thorac Soc        ISSN: 1546-3222


  167 in total

1.  Oxidative stress and airway inflammation in severe exacerbations of COPD.

Authors:  E M Drost; K M Skwarski; J Sauleda; N Soler; J Roca; A Agusti; W MacNee
Journal:  Thorax       Date:  2005-04       Impact factor: 9.139

2.  Airway inflammation during stable and acutely exacerbated chronic obstructive pulmonary disease.

Authors:  K Fujimoto; M Yasuo; K Urushibata; M Hanaoka; T Koizumi; K Kubo
Journal:  Eur Respir J       Date:  2005-04       Impact factor: 16.671

Review 3.  Systemic corticosteroids for acute exacerbations of chronic obstructive pulmonary disease.

Authors:  R R Wood-Baker; P G Gibson; M Hannay; E H Walters; J A E Walters
Journal:  Cochrane Database Syst Rev       Date:  2005-01-25

4.  Biopsy neutrophilia, neutrophil chemokine and receptor gene expression in severe exacerbations of chronic obstructive pulmonary disease.

Authors:  Yusheng Qiu; Jie Zhu; Venkata Bandi; Robert L Atmar; Keith Hattotuwa; Kay K Guntupalli; Peter K Jeffery
Journal:  Am J Respir Crit Care Med       Date:  2003-07-11       Impact factor: 21.405

5.  Resolution of bronchial inflammation is related to bacterial eradication following treatment of exacerbations of chronic bronchitis.

Authors:  A J White; S Gompertz; D L Bayley; S L Hill; C O'Brien; I Unsal; R A Stockley
Journal:  Thorax       Date:  2003-08       Impact factor: 9.139

6.  Impact of oseltamivir treatment on influenza-related lower respiratory tract complications and hospitalizations.

Authors:  Laurent Kaiser; Cynthia Wat; Tracy Mills; Paul Mahoney; Penelope Ward; Frederick Hayden
Journal:  Arch Intern Med       Date:  2003-07-28

7.  Epidemiology of respiratory viruses in patients hospitalized with near-fatal asthma, acute exacerbations of asthma, or chronic obstructive pulmonary disease.

Authors:  Wan C Tan; Xueyu Xiang; Diwen Qiu; Tze Pin Ng; Sin F Lam; Richard G Hegele
Journal:  Am J Med       Date:  2003-09       Impact factor: 4.965

Review 8.  Canadian guidelines for the management of acute exacerbations of chronic bronchitis.

Authors:  Meyer S Balter; Jacques La Forge; Donald E Low; Lionel Mandell; Ronald F Grossman
Journal:  Can Respir J       Date:  2003 Jul-Aug       Impact factor: 2.409

9.  The proportional Venn diagram of obstructive lung disease: two approximations from the United States and the United Kingdom.

Authors:  Joan B Soriano; Kourtney J Davis; Bobbie Coleman; George Visick; David Mannino; Neil B Pride
Journal:  Chest       Date:  2003-08       Impact factor: 9.410

10.  Respiratory viral infections in patients with chronic, obstructive pulmonary disease.

Authors:  J David Beckham; Ana Cadena; Jiejian Lin; Pedro A Piedra; W Paul Glezen; Stephen B Greenberg; Robert L Atmar
Journal:  J Infect       Date:  2005-05       Impact factor: 6.072

View more
  4 in total

1.  Relation between chronic obstructive pulmonary disease and antibiotics.

Authors:  Salvador Sialer; Liapikou Adamantia; Mónica Guerrero; Antoni Torres
Journal:  Curr Infect Dis Rep       Date:  2012-06       Impact factor: 3.725

2.  Up-regulation of MUC18 in airway epithelial cells by IL-13: implications in bacterial adherence.

Authors:  Glenn C Simon; Richard J Martin; Sean Smith; Jyoti Thaikoottathil; Russell P Bowler; Stephen J Barenkamp; Hong Wei Chu
Journal:  Am J Respir Cell Mol Biol       Date:  2011-01-14       Impact factor: 6.914

3.  Utility of serum procalcitonin values in patients with acute exacerbations of chronic obstructive pulmonary disease: a cautionary note.

Authors:  Ann R Falsey; Kenneth L Becker; Andrew J Swinburne; Eric S Nylen; Richard H Snider; Maria A Formica; Patricia A Hennessey; Mary M Criddle; Derick R Peterson; Edward E Walsh
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2012-02-23

4.  Novosphingobium and its potential role in chronic obstructive pulmonary diseases: insights from microbiome studies.

Authors:  Alleluiah Rutebemberwa; Mark J Stevens; Mario J Perez; Lynelle P Smith; Linda Sanders; Gregory Cosgrove; Charles E Robertson; Rubin M Tuder; J Kirk Harris
Journal:  PLoS One       Date:  2014-10-23       Impact factor: 3.240

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.